The Mitochondrial Medicine & Neurogenetics (MMN) group

The Mitochondrial Medicine & Neurogenetics (MMN) group is a clinical and research unit devoted to the diagnosis, study and treatment of inherited neurological diseases with special focus on mitochondrial disease.

Dopamine transporter (DAT) imaging shows the uptake of a radioactive tracer in the nigrostriatal terminals (bright areas). This reflects the integrity and density of the dopaminergic neurons in the substantia nigra. Patients with POLG mutations (C) have severe nigrostriatal degeneration, which is more pronounced than even in patients with Parkinson's disease (B). The scan of a healthy person (A) is shown for comparison. Tzoulis et al., Brain 2013.

Main content

Our team consists of clinical and basic scientists with a wide range of skills and expertise in the fields of clinical neurology, biochemistry, molecular and population genetics.

The Mitochondrial Medicine & Neurogenetics (MMN) group includes the Centre for Mitochondrial Medicine, a highly specialised unit dedicated to the investigation, diagnosis and follow-up of patients with mitochondrial disorders.

The major research areas within the MMN group are mitochondrial disease and movement disorders, including parkinsonism, dystonia and ataxia. We conduct multidisciplinary, translational research that include clinical and laboratory studies, as well as studies of animal models. For more details see our “Research” section.

Our goal is to promote better diagnosis and treatment of inherited neurological diseases by conducting state of the art research that will elucidate disease mechanisms and define new treatments.